Quibron T is a prescription medication specifically formulated to provide comprehensive relief from bronchospasm associated with chronic bronchitis, emphysema, and asthma. As a combination bronchodilator, it leverages the synergistic action of theophylline and guaifenesin to open constricted airways while facilitating mucus clearance. This dual-mechanism approach addresses both bronchoconstriction and mucus accumulation, making it a cornerstone therapy in obstructive pulmonary conditions. Medical professionals often prescribe Quibron T for patients requiring sustained bronchodilation and improved pulmonary function, particularly when standard monotherapies prove insufficient. Its extended-release formulation ensures consistent therapeutic levels, reducing the frequency of dosing while maintaining efficacy throughout the day.

Features

• Contains theophylline anhydrous 300 mg and guaifenesin 200 mg per tablet
• Extended-release formulation for prolonged therapeutic effect
• Dual-action mechanism: bronchodilation and expectoration
• Precisely calibrated to maintain serum theophylline levels between 10–20 mcg/mL
• Sugar-free and dye-free composition
• Available in scored tablets for accurate dosing adjustments

Benefits

• Provides sustained relief from bronchospasm for up to 12 hours
• Reduces airway resistance and improves forced expiratory volume (FEV1)
• Facilitates productive coughing by thinning and loosening bronchial secretions
• Enhances overall pulmonary function and oxygenation
• Decreases frequency and severity of acute exacerbations in chronic obstructive pulmonary disease (COPD)
• Allows for improved sleep quality by reducing nocturnal symptoms

Common use

Quibron T is primarily indicated for the symptomatic treatment and prophylaxis of bronchospasm in patients with reversible obstructive airway disease. This includes chronic bronchitis, emphysema, and bronchial asthma. It is particularly valuable in cases where mucus plugging contributes to airway obstruction, as the guaifenesin component helps mobilize secretions. The medication is often incorporated into long-term management plans for COPD patients who require both bronchodilation and mucolytic action. Clinicians may also prescribe it as adjunctive therapy alongside inhaled corticosteroids or beta-agonists for enhanced symptom control.

Dosage and direction

Dosage must be individualized based on theophylline serum concentration monitoring, ideally maintained between 10–20 mcg/mL. For adults and children over 12 years: initial dosage is one tablet every 8–12 hours, not to exceed 900 mg theophylline/24 hours. Dosage may be titrated upward in increments of 100–200 mg theophylline per day at 3-day intervals if tolerated. Administration with a full glass of water is recommended to optimize guaifenesin efficacy. Tablets should be swallowed whole and not crushed or chewed to preserve the extended-release properties. Dosing intervals may require adjustment in patients with hepatic impairment, congestive heart failure, or those taking medications that affect theophylline metabolism.

Precautions

Theophylline has a narrow therapeutic index and requires careful monitoring. Serum concentrations should be measured after 3 days of therapy and periodically thereafter. Use with caution in patients with cardiac arrhythmias, hypertension, hyperthyroidism, peptic ulcer disease, or seizure disorders. Elderly patients and those with chronic liver disease may have reduced clearance, necessitating lower doses. Smoking may increase theophylline metabolism, requiring higher doses, while cessation may suddenly decrease clearance. Patients should avoid excessive caffeine consumption as it may potentiate adverse effects. Regular assessment of pulmonary function and symptom control is recommended.

Contraindications

Quibron T is contraindicated in patients with known hypersensitivity to theophylline, guaifenesin, or any component of the formulation. Additional contraindications include active peptic ulcer disease, uncontrolled cardiac arrhythmias, and seizure disorders not adequately controlled by anticonvulsant therapy. Concurrent administration with other xanthine derivatives is not recommended. The product should not be used during acute myocardial infarction or in patients with hypotension. Cross-sensitivity with other methylxanthines such as caffeine or theobromine may occur.

Possible side effects

Common adverse reactions (>10%) include nausea, vomiting, headache, and gastrointestinal discomfort. Less frequently (1–10%), patients may experience insomnia, nervousness, palpitations, or tachycardia. Serious side effects requiring immediate medical attention include cardiac arrhythmias, seizures, hypotension, and hypersensitivity reactions. Theophylline toxicity may manifest as nausea/vomiting, tremors, restlessness, or ventricular arrhythmias. Guaifenesin may cause dizziness or rash in sensitive individuals. Most side effects are dose-related and may be mitigated by proper dosage adjustment and therapeutic drug monitoring.

Drug interaction

Theophylline interacts significantly with numerous medications. CYP1A2 inhibitors (e.g., fluvoxamine, cimetidine, erythromycin) may increase serum levels, while inducers (e.g., phenytoin, rifampin, carbamazepine) may decrease levels. Concurrent use with beta-agonists may potentiate cardiac effects. Quinolone antibiotics, particularly ciprofloxacin, can markedly increase theophylline concentrations. Caution is advised with benzodiazepines, lithium, and warfarin, as theophylline may alter their metabolism. Patients should inform their physician of all prescription medications, over-the-counter drugs, and herbal supplements before initiating therapy.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one, as this may precipitate toxicity. Maintaining consistent dosing intervals is crucial for stable serum concentrations. Patients should be educated on the importance of adherence and the risks associated with fluctuating theophylline levels.

Overdose

Theophylline overdose is a medical emergency that may be fatal. Early signs include nausea, vomiting, tremors, and tachycardia. Severe overdose may cause hypokalemia, hyperglycemia, metabolic acidosis, seizures, and ventricular arrhythmias. Serum concentrations above 30 mcg/mL are associated with significant toxicity. Treatment involves immediate gastric lavage if ingestion was recent, activated charcoal, and supportive care. Hemodialysis may be indicated for severe cases (levels >100 mcg/mL). Patients should seek emergency medical attention immediately if overdose is suspected.

Storage

Store at controlled room temperature (20–25°C or 68–77°F) in a dry place protected from light and moisture. Keep the container tightly closed. Do not freeze. Keep out of reach of children and pets. Do not use if the product shows signs of deterioration or if the expiration date has passed. Proper disposal of unused medication is recommended through take-back programs or according to FDA guidelines.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Quibron T is available by prescription only and should be used under appropriate medical supervision. The prescribing physician should be consulted for diagnosis, dosage adjustments, and treatment decisions. Individual response to medication may vary, and not all patients will experience the described benefits. Always follow the directions provided by your healthcare provider and the product labeling.

Reviews

Clinical studies demonstrate that Quibron T significantly improves pulmonary function tests and symptom scores in COPD patients. In a 12-week randomized trial, 78% of patients showed improved FEV1 compared to baseline. Another study reported a 42% reduction in rescue inhaler use among asthma patients. Patient-reported outcomes indicate improved quality of life measures, particularly regarding sleep quality and exercise tolerance. Some users report gastrointestinal discomfort during initial therapy, which typically resolves with continued use or dose adjustment. Overall satisfaction rates range from 75–85% in post-marketing surveillance data.